Last reviewed · How we verify
NCT03814967
Effects of Brain Stimulation on Higher-Order Cognition
NA trial testing Transcranial Direct Current Stimulation in Schizophrenia in 86 participants. Completed in 31 May 2025.
31 May 2025
Quick facts
| Lead sponsor | University of California, Davis |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 86 |
| Start date | 22 May 2019 |
| Primary completion | 31 May 2025 |
| Estimated completion | 31 May 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Transcranial Direct Current Stimulation
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
Sponsor
University of California, Davis
Who can join
Adults 18 to 50, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to better understand the neural correlates of higher-order cognition, both in the healthy brain and in schizophrenia, and to determine how these mechanisms are modulated by transcranial direct current stimulation (tDCS) at frontal and occipital scalp sites. Testing the effects of tDCS at these scalp sites on cognitive task performance will help us understand the roles of the brain regions corresponding to these sites during higher-order cognitive processing (language comprehension, cognitive control, and related attention and memory processes). Behavioral and electrophysiological (EEG) measures will be used to assess cognitive performance. The investigator's overarching hypothesis is that stimulating prefrontal circuits with tDCS can improve cognitive control performance, and ultimately performance on a range of cognitive tasks, as compared to stimulating a different cortical region (occipital cortex) or using sham stimulation. This study is solely intended as basic research in order to understand brain function in healthy individuals and individuals with schizophrenia. This study is not intended to diagnose, cure or treat schizophrenia or any other disease.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Finding the Right Dose: NMDA Receptor-Modulating Treatments for Cognitive and Plasticity Deficits in Schizophrenia and the Role of Pharmacodynamic Target Engagement.
Sehatpour P, Kantrowitz JT. · · 2025 · cited 12× · PMID 39218136 · DOI 10.1016/j.biopsych.2024.08.019
Verify or expand the search:
- PubMed search for NCT03814967
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Transcranial Direct Current Stimulation
Trials testing the same drug.
- NCT07496645 — EFFECT OF ANODAL TRANSCRANIAL DIRECT CURRENT STIMULATION ON NAMING IN APHASIC PATIENTS WITH ACUTE ISCHEMIC STROKE · Phase 3 · not yet recruiting
- NCT07395531 — Effect of Repetitive Bihemispheric Anodal Transcranial Direct Current Stimulation on Motor Function of Patients With Par · Phase 3 · not yet recruiting
- NCT07212634 — Cerebellar Transcranial Direct Current Stimulation for Dysphagia After Supratentorial Stroke · NA · not yet recruiting
- NCT07319143 — The Effect of Transcranial Direct Current Stimulation (tDCS) in Improving Emotion Health · NA · recruiting
- NCT06039605 — Priming Expectations and Motor Learning With tDCS · NA · completed
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other University of California, Davis trials
Trials by the same sponsor.
- NCT07024498 — Coordinating Outpatient bupreNorphiNe for Emergency Care and Continuing Treatment · NA · not yet recruiting
- NCT07322133 — Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE) · Phase 4 · recruiting
- NCT07384767 — Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing · Phase 2 · not yet recruiting
- NCT07267494 — Image-Guided Herniorrhaphy Study · NA · not yet recruiting
- NCT04614714 — Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants · Phase 2, PHASE3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03814967 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, Davis
- Last refreshed: 29 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03814967.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing